Several clinical trials are investigating the use of Perk inhibitors in various types of cancers. These trials aim to assess the safety, efficacy, and optimal dosing of these inhibitors. Results from these trials will provide valuable insights into whether Perk can be effectively targeted in cancer therapy and what combination therapies may yield the best outcomes.